SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?


To: arun gera who wrote (184079)2/16/2022 4:47:56 PM
From: TobagoJack  Read Replies (1) | Respond to of 217752
 
Am not sure, but it is possible, and I am guessing, but shall at another time ping the very busy doctor, that what we best do is to get a jolt of antibody mobilization by mRNA vaxx liquid, and do call-of-duty reserve calling, for T cell rallying by tradVaxx inactive virus liquid, and thus his points (4), (5), (7), (8), and (9)

Message 33711902






To: arun gera who wrote (184079)2/16/2022 4:52:03 PM
From: TobagoJack  Respond to of 217752
 
Might be, for whatever reasons, mRNA rallies antibodies, and
Inactivated tradVaxx calls up T cells

Together, they win
Apart, less good



To: arun gera who wrote (184079)2/16/2022 5:03:02 PM
From: TobagoJack  Respond to of 217752
 
China mRNA on way, as if ‘they’ know something, being deliberately different from the Pfizer liquid

The rubbish in press already out in some force, and that might tell us all we need to know

uk.news.yahoo.com

COVID: China is developing its own mRNA vaccine – and it's showing early promise

Tue, 15 February 2022, 9:03 pm

Eoghan De Barra, Consultant in Infectious Diseases, Beaumont Hospital, and Senior Lecturer, RCSI University of Medicine and Health Sciences

China, the country that first detected the novel coronavirus, remains one of the few not to have imported one of the exceptionally effective mRNA COVID vaccines developed by Pfizer and Moderna. Instead, it has so far relied on vaccines developed by two Chinese companies, Sinovac and Sinopharm. However, this may be set to change. China is now developing its own mRNA vaccine.

Both the Sinovac and Sinopharm vaccines use a traditional design, containing whole forms of the coronavirus that have been inactivated – a tried-and-tested way of making vaccines that work. However, while these vaccines were initially quite good at stopping people getting symptomatic COVID, this protection waned significantly over time. These vaccines also offer poor protection against infection with omicron. This has put pressure on China to develop more effective vaccines, as it is pursuing a strict containment policy with the virus.

The mRNA vaccines work in a different way. They deliver a snippet of the coronavirus’s genetic code into the body, housed inside a lipid droplet. Once this gets inside cells, the code gets read and the cells produce copies of a key part of the coronavirus, its spike protein. The immune system then sees these spike proteins and mounts a response to them, generating immunity against the full virus should it be encountered in the future.

The mRNA vaccines initially generated high levels of protection against getting COVID. And while the protection offered by two doses wanes over time and offers little protection against infection with omicron, the mRNA vaccines appear to offer the best protection against an omicron infection when used as boosters. They also continue to offer very impressive protection against severe disease. Early results suggest a third dose of Sinovac, in comparison, is unable to stop infection with the new variant (though these results are still in preprint, meaning they’re awaiting review by other scientists).

Enter ARCoVThe mRNA vaccine technology therefore looks like it will offer the best protection against COVID in the future – hence China’s development of such a vaccine. But it hasn’t just jumped on the bandwagon. Development of ARCoV, China’s candidate mRNA vaccine, commenced in March 2020. The technology used is very similar to that in the Pfizer and Moderna vaccines, using modified messenger RNA from the virus, housed in a lipid droplet, to stimulate immunity.


Existing mRNA vaccines create whole copies of the virus’s spike proteins (red). ARCoV just makes a small part of the spike. US CDC/Wikimedia Commons

But rather than getting the immune system to respond to the full spike protein of the virus like the Pfizer and Moderna vaccines do, ARCoV gets the body to make copies of the receptor binding domain (RBD), a key subpart of the virus’s spike protein that it uses to attach to and enter cells. This part of the virus seems to be especially recognisable by the immune system, which suggests that targeting it could have a particularly good protective effect.

Another potential advantage ARCoV has over the earlier mRNA vaccines is that it is stable at 2-8°C for at least a month, which would make transporting, storing and delivering the vaccine much easier.

How well does it work?The results of an initial study of the vaccine in humans, where 120 volunteers were vaccinated with varying doses, were published in January 2022 in the Lancet. The vaccine was found to be safe, but there was a higher rate of fever after vaccination, especially at higher doses, than was seen in early studies of the other mRNA vaccines. However, these fevers were short lived.

The study also measured the levels of antibodies and T cells against the virus that the volunteers produced after being vaccinated. The best antibody and T-cell responses were seen in the intermediate-dose group, with higher doses leading to a lower response. It’s not 100% clear why this was the case, but this may be due to the body’s non-specific immune response (its general purpose defences that attack all sorts of foreign invaders) destroying the vaccine at higher doses before it could have its desired effect.

And even in those receiving the intermediate dose, the antibodies and T-cell responses recorded were also lower than those generated by the existing mRNA vaccines, which raises questions around how effective this vaccine will be. However, the results of a much larger ongoing study will be needed to properly assess this. That larger trial will involve over 28,000participants across China, Mexico and Indonesia and will be using the intermediate dose that was shown to work best in this initial study.

Some interim results are to be expected in the coming months. There’s also another trial underway that’s studying giving ARCoV as a booster following the Sinovac or Sinopharm vaccines. The results of these studies – both in terms of whether there are any adverse events and how well ARCoV prevents infection, severe disease and death – will dictate the future of this vaccine and China’s future approach to COVID. Should it fail, will China seek to purchase the some of the proven Pfizer and Moderna mRNA vaccines instead? Time will tell.

This article is republished from The Conversation under a Creative Commons license. Read the original article.

The Conversation

Eoghan De Barra receives funding from Health Research Board of Ireland

Sent from my iPad



To: arun gera who wrote (184079)2/16/2022 5:04:13 PM
From: TobagoJack  Respond to of 217752
 
Rubbish it MSM




To: arun gera who wrote (184079)2/16/2022 5:10:41 PM
From: TobagoJack  Respond to of 217752
 
Translation,

New fangled liquids gets strong boost from inactivated vaccine, would be such headlines once Pfizer has one

reuters.com

Sinovac regimen gets strong boost from Pfizer, AstraZeneca or J&J COVID shots - study
Reuters
January 25, 20225:37 AM GMT+8Last Updated 23 days ago


Vials of Chinese Sinovac's CoronaVac vaccine against coronavirus disease (COVID-19) pictured inside the newly inaugurated production lab designated to manufacture the vaccine, in Constantine, Algeria September 29, 2021. REUTERS/Ramzi Boudina

Jan 24 (Reuters) - A third booster dose of a COVID-19 vaccine made by AstraZeneca, Pfizer-BioNTech or Johnson & Johnson increases antibody levels significantly in those who have previously received two doses of Sinovac's (SVA.O) CoronaVac shot, a study has found.

Reporting by Aby Jose Koilparambil and Pushkala Aripaka in Bengaluru; Editing by Ramakrishnan M.

You have reached your article limit

Register for FREE to continue using Reuters.comFree registration gives you access to:

Unmatched, global, round-the-clock news

Hand-picked insights that are easy to find and use

Our Daily Briefing newsletter, delivering the day's headlines right to your inbox

Register now

Already registered? Sign in

Terms & Conditions apply

Are you a Thomson Reuters legal customer? Learn more

Sent from my iPad



To: arun gera who wrote (184079)2/16/2022 6:08:57 PM
From: TobagoJack1 Recommendation

Recommended By
marcher

  Respond to of 217752
 
good-bad-news, that ...

scmp.com

Omicron infection after vaccination may protect against other coronavirus strains, study finds

- South African study says vaccination followed by Omicron infection may stop Delta and other variants, but immune protection not observed in unvaccinated people

- Meanwhile, US researchers suggest breakthrough infection caused by other strains after two mRNA shots won’t prevent Omicron

An Omicron breakthrough infection after vaccination could offer protection against other strains – but that protection was not observed in unvaccinated people, a study in South Africa, has suggested.

Meanwhile, another study, in the US, found that immunity from a breakthrough Covid-19 case caused by other variants – after two doses of an mRNA vaccine – will not be enough to stop an Omicron infection.

In the US, the team from Ohio State University, led by Dr Shan-Lu Liu, examined the neutralising antibody response against the Alpha, Beta, Delta and Omicron variants in 48 health care workers who were vaccinated with either the Pfizer or Moderna mRNA vaccines.

Blood samples were collected before vaccination, after the first dose, and twice after the second dose, according to the paper published in the journal Science Translational Medicine on Tuesday.

The researchers observed a decline in the neutralising antibodies – a predictor of immune protection – from one month to six months after the two doses were given.

All four variants of concern consistently showed lower neutralising antibodies compared to a strain at the early stage of the pandemic, with the Omicron variant having the most pronounced resistance.

At six months, about 56.3 per cent of health care workers taking part in the study had levels below the detection limit against Delta, while 89.6 per cent were below that limit for Omicron.

Twelve of the health care workers were found to be infected with the coronavirus at different phases of vaccination and their level of neutralising antibodies was about six times higher six months later than the subjects who had not been infected.

However, 30 per cent of the infected people still had no detectable level of neutralising activity, compared to 60 per cent of the uninfected health care workers.

The researchers suggested that the ability of Omicron to evade immunity highlighted the need for booster shots.

“We observed a profound escape of the Omicron variant from mRNA vaccine-induced immunity, even at three to four weeks after the second dose … Further, this escape was not rescued in most health care workers by breakthrough infection,” the paper said.

“Although breakthrough infection can boost neutralising antibody responses, it appears largely ineffective for providing protection from Omicron, at least for individuals infected before the Omicron wave.”

In South Africa, meanwhile, a study led by Dr Penny Moore at the National Institute for Communicable Diseases, under the National Health Laboratory Service in Johannesburg, looked at the neutralising effect of Omicron infection in combination with particular vaccines.

Moore’s study found an Omicron infection induced antibodies against that variant in unvaccinated people but neutralising was “significantly compromised” against the Beta and Delta strains.

In contrast, people who had received the Johnson & Johnson or Pfizer vaccines before being infected with Omicron showed greatly improved cross-reactivity, with high antibody titres against a variant from the early stage of the pandemic, as well as the Beta, Delta and Omicron strains.

“In the absence of vaccination, Omicron-elicited humoral responses, while potent against the matched Omicron spike, show significantly less activity against variants of concern. Thus, while highly immunogenic, Omicron does not elicit cross-neutralising responses,” the authors wrote in a paper posted on MedRxiv.org without peer review.

“This may result in risk of reinfection in this unvaccinated group with other variants that continued to circulate and evolve in South Africa at the time of this study, albeit at low levels, including Beta, Delta.”

The research was based on limited samples, with only 20 unvaccinated and seven vaccinated people infected during the Omicron wave. The team said the findings had implications for the design of second-generation vaccines based on Omicron.

Animal studies by Moderna have shown that primates given Omicron-specific vaccines induced antibody titres at levels similar to those given its original mRNA vaccine.

“Overall, these data suggest that boosting individuals with or without immunity with vaccines specific for Omicron is unlikely to be superior to existing regimens,” the South African researchers said.



To: arun gera who wrote (184079)2/16/2022 6:34:42 PM
From: TobagoJack  Read Replies (1) | Respond to of 217752
 
Also, I suspect vaccination is just and merely-only a part of the Covid-fight equation

Here be an article by usually China-China-China bashing WSJ

wsj.com

China’s ‘Zero-Covid’ Policy Holds Lessons for Other Nations

Enormous resources, local cooperation enable China to suppress infections with less disruption to life than in countries where pandemic still rages

Greg Ip
Updated Feb. 16, 2022 2:45 pm ET



Highly organized and available testing, as at a site in January in Beijing, is a critical element in China’s aggressive approach to address every Covid-19 infection.Photo: Kevin Frayer/Getty Images
It is difficult for westerners to evaluate China’s Covid-19 response dispassionately. Mistrust still runs high over China’s muzzling of informationabout the virus in Wuhan in late 2019, its refusal to accept that the pandemic originated there and failure to cooperate more with international investigations over its origins. China’s intrusive measures for tracking, tracing and isolating infected people are seen as an extension of a surveillance state that would be intolerable in a democracy with individual rights. Indeed, the Chinese Communist Party touts its Covid-19 success as proof its governance is superior to American-style democracy.

And yet this geopolitical tension tends to muddy zero Covid’s achievements and its lessons for other countries, including democracies. It appears to have delivered what every country sought two years ago: low deaths with the least possible economic disruption. While there are questions over the reliability of China’s official Covid death toll, it appears to rank among the world’s lowest on a per capita basis, and its gross domestic product finished 2021 roughly where pre-pandemic trends predicted.

China’s ‘Zero-Covid’ Policy Creates New Supply-Chain Worries

0:00 / 3:29

0:37

China’s ‘Zero-Covid’ Policy Creates New Supply-Chain Worries

To keep out Covid-19, China closed some border gates late last year, leaving produce to rot in trucks. Restrictions like these and rules at some Chinese ports, the gateways for goods headed to the world, could cascade into delays in the global supply chain. Photo composite: Emily Siu

It is true, as critics claim, that zero Covid can’t be sustained indefinitely. China will eventually have to coexist with a virus that is permanently entrenched in the human population. Hong Kong’s spreading outbreak illustrates how difficult test, trace and isolate becomes once infections are widespread enough.

Yet it is worth studying how mainland China has sustained zero Covid this long. China put enormous resources behind the effort, most importantly on testing capacity: A city of fewer than five million people is expected to screen every inhabitant using sensitive PCR tests in two days, and a city of more than five million in three days. The port city of Tianjin tested its entire population of 14 million in 4.5 hours last month, state media reported. By contrast, testing became backlogged or unavailable for many in numerous U.S. cities during the Omicron wave.

Beijing also has modified zero Covid to make it less disruptive. The lockdown of Xi’an, a city of 13 million, for a month through late January is the exception. Under a more targeted approach dubbed “dynamic clearing,” restrictions typically cover just a district, a neighborhood or a building. “Some localities endure tough restrictions and disruption for a short period of time so that most of the country can exist without restrictions most of the time—a balance that so far has enjoyed reasonable popular support,” Cui Ernan of Gavekal Dragonomics, a China-focused research service, wrote last month.

This hasn’t been costless. China’s consumer spending has been hit hard by lockdowns and travel restrictions, though strong exports have offset the impact on overall growth. Yanzhong Huang, a health expert at the Council on Foreign Relations in New York, said 4.4 million small businesses closed in the first 11 months of last year while just 1.3 million new ones registered. China, he estimates, spent nearly $100 billion on domestic vaccines that are far less effective than western mRNA shots that it refuses to approve. Those under lockdown have suffered inconvenience, disrupted travel and family separations, he said.



People registered at a Covid-19 testing facility in Hong Kong, which has struggled in recent weeks with an outbreak.Photo: Chan Long Hei/Bloomberg News

Yet life was much less affected by Covid-19 in China than in other countries last year, according to an index of restrictions and mobility developed by Goldman Sachs. Elsewhere, waves of the pandemic have hurt business, closed schools and triggered mask mandates while incurring steep, unquantifiable costs in illness and death. Disruptions and deaths will no doubt mount when China eventually lifts zero Covid, but it has bought time to build up vaccines, therapies and healthcare facilities to mitigate the impact.

Of course, citizens deprived of their freedom or livelihoods can’t vote the Communist Party out of office or protest in the streets. Still, ordinary Chinese appear to support and willingly cooperate with zero Covid because they see its benefits.

That suggests there is more to China’s success than an absence of democracy. A recent study in Lancet sought to explain why some countries had lower Covid-19 infection and death rates through last September. It controlled for factors such as population density, per capita income, age and pre-existing conditions. One finding: “There is no relationship between democracy and performance that we could find in this pandemic,” said Thomas Bollyky, one of the authors and director of the global health program at the Council on Foreign Relations. The death rate is low in autocratic China but high in autocratic Russia; low in democratic Taiwan but high in the democratic U.S.

Share of respondents who:Source: World Values SurveyNote: Surveys conducted from 2017 to 2020. Sample?sizes range from 1,057 to 4,018.

Have a great deal / quite a lot of?confidence in governmentSay most people can be trustedChinaRussiaTaiwanSouth KoreaNew ZealandCanadaJapanDenmarkU.S.GermanyU.K.Brazil0%255075100



What did make a difference, the study found, is trust. The more citizens trust the government, or each other, the more effectively a country dealt with Covid-19. Intuitively, citizens who trust the government are more likely to complywith social distancing, contact tracing and mask and vaccine mandates. Where trust is lacking, citizens are less likely to comply and governments less likely to ask. Interpersonal trust encourages citizens to do things that protect others, and to believe others will do the same.

According to the World Values Survey, trust in government is high in China and low in the U.S. Mr. Bollyky acknowledged survey respondents in autocratic countries may censor their views. But even leaving out China, he said the results held. Covid-19 outcomes generally are better where more people trust the government (New Zealand, South Korea) or each other (Denmark, Canada).

The lesson of China’s success, then, isn’t that autocracy is superior. It’s that U.S. democracy needs to work better.

Write to Greg Ip at greg.ip@wsj.com



To: arun gera who wrote (184079)2/18/2022 9:48:02 PM
From: Pogeu Mahone1 Recommendation

Recommended By
marcher

  Respond to of 217752
 
Contrary to Common Belief:

BA.2 subvariant of Omicron on the rise, research shows that it can slip past antibodies of other variants

A new study suggests BA.2, the subvariant of Omicron, can cause more severe disease than the original Omicron BA.1.

COVID-19
By: Dr. Partha NandiPosted at 3:19 PM, Feb 18, 2022 and last updated 5:25 PM, Feb 18, 2022
(WXYZ) — A new study suggests BA.2, the subvariant of Omicron, can cause more severe disease than the original Omicron BA.1. It also appears to be more resistant to some treatments used to fight infection.

Lab experiments from Japan found BA.2 is very different from the original Omicron variant. It has dozens of gene changes that are so distinct that researchers feel that BA.2 should get its Greek letter.

How did the scientists discover that BA.2 can cause more severe disease than the original Omicron variant? Well, in lab studies, animals infected with BA.2 ended up getting sicker than animals infected with BA.1. BA.2 also caused worse lung function compared to BA.1. When tissue samples were examined, more damage was seen in the animals with BA.2 than with BA.1.

What's concerning is this study also found the BA.2 lineage can replicate itself faster than BA.1. It’s better at making cells stick to each other. If large clumps develop, the medical term is called Syncytia, which allows the virus to make copies of itself much faster. Delta was good at this, which is one reason scientists believed it was so damaging to the lungs.


Real world evidence is mixed regarding BA.2 and how severe it can be. For example, if you look at the United Kingdom and South Africa, hospitalizations have declined. But in Denmark, hospitalizations and deaths have been on the rise.

A study found that BA.2 can be resistant to Sotrovimab. That’s a monoclonal antibody treatment given to people who are at high risk of developing severe disease. Blood tests suggest BA.2 can slip past antibodies of people who’ve been infected with the Alpha and Delta variants. Research suggests BA.2 is between 30 and 50% more contagious than the original Omicron variant.

Right now, BA.2 only accounts for roughly 4% of US COVID-19 infections. Blood tests show people recently infected with BA.1. The original Omicron has some protection against infection with BA.2, especially if they were also vaccinated. Those who have avoided the infection, getting a booster shot restored protection, making illness after infection about 74% less likely.

Additional Coronavirus information and resources:

View a global coronavirus tracker with data from Johns Hopkins University.